Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma

NCT01682187 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01682187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01682187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
December 15, 2005
Completion date
September 30, 2024
Enrollment
66 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioma